Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 16

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 2
Chunk 16
---
 six months ended June 30, 2025 versus 2024, respectively, primarily due to both the timing of orders placed for veterinary use and the sales mix of vial sizes.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 46

The following tables provide a summary of activity with respect to our sales-related allowances and accruals related to EXPAREL and ZILRETTA for the six months ended June 30, 2025 and 2024 (in thousands):

June 30, 2025ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision702 6,918 11,189 76,044 1,813 96,666 Payments(267)(6,838)(11,320)(76,113)(1,815)(96,353)Balance at June 30, 2025$2,035 $1,388 $4,744 $4,794 $1,705 $14,666 

June 30, 2024ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision1,014 6,199 9,985 54,533 1,334 73,065 Payments(664)(6,287)(9,850)(55,058)(715)(72,574)Balance at June 30, 2024$2,218 $1,220 $3,832 $5,345 $1,794 $14,409 

Total reductions of gross product sales from sales-related allowances and accruals were $96.7 million and $73.1 million, or 21.7% and 17.6% of gross product sales, for the six months ended June 30, 2025 and 2024, respectively. The overall 4.1% increase in sales-related allowances and accruals as a percentage of gross